Longeveron Inc. (NASDAQ: LGVN) announced that additional analysis of Phase 2a clinical trial data for its stem cell therapy laromestrocel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE